Biogen has settled its Tecfidera patent fight with Forward Pharma for a whopping $1.25 billion in upfront cash, plus potential royalties, sending Forward'…

If there was any doubt that the oncology market is set to reach unprecedented heights, FiercePharma's top 15 list of cancer drugs in 2022 should eliminate…

President-elect Trump says he plans to flex his Twitter muscles to bring down drug prices and force pharma manufacturing to the U.S.

The sun has set on the J.P. Morgan Healthcare Conference, but we're still digesting the multicourse meal of news and commentary. Here's our menu.

The U.S. Justice Department is demanding Shire cough up $350 million to settle a Dermagraft marketing probe, citing “flagrant and systemic kickback activity.”

When it comes to tech, Novartis' execs think the company can be on the “leading edge” in the space.

In this week's FiercePharmaAsia wrap-up, Takeda has offered $5.2 billion to buy Ariad and made a $125 deal with Maverick on T-cell therapy R&D,…

An appeals court ruled against generics challenger Teva, potentially protecting Eli Lilly's cancer med Alimta until 2022.

Mylan is taking another hit tied to its EpiPen pricing controversy.